COMMENTARY
With No Pilot at Helm, Pharma Industry Embroiled in Confusion with Voluntary Funding Disclosures
Drug makers affiliated with the Japan Pharmaceutical Manufacturers Association (JPMA) have finally begun disclosing details of the funding they provided to healthcare professionals and patients’ organizations in FY2013 in accordance with the JPMA’s transparency guidelines. In the vanguard was Pfizer…
To read the full story
COMMENTARY
- Are Technical Discussions Enough for Japan’s CEA System?
May 25, 2026
- Shift Underway in Pharma Workforce as Sales Roles Shrink, Manufacturing Rises
April 28, 2026
- Gene Therapies Expand into AMD, Raising Promise and Cost Concerns
April 24, 2026
- Challenges in a Post-AG Era: Ensuring a Reliable Supply System
April 6, 2026
- Japan’s FY2026 R&D Tax Credit Reform Wins Broad Industry Backing
April 1, 2026
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…





